Distinguished in Venous Thromboembolism (VTE)

Eduardo Ramacciotti

Hospital E Maternidade Dr. Christóvão Da Gama, 
Sao Paulo, SP, BR 
Distinguished in Venous Thromboembolism (VTE)
Hospital E Maternidade Dr. Christóvão Da Gama, 
Sao Paulo, SP, BR 
OverviewLocationsClinical Research

Overview

Eduardo Ramacciotti practices in Sao Paulo, Brazil. Mr. Ramacciotti is rated as a Distinguished expert by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Venous Thromboembolism (VTE), Mesenteric Venous Thrombosis, COVID-19, Deep Vein Thrombosis, and Intrauterine Device Insertion.

His clinical research consists of co-authoring 69 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 28 articles in the study of Venous Thromboembolism (VTE).

Gender
Male

Locations

Hospital E Maternidade Dr. Christóvão Da Gama, Sao Paulo, SP, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: Cannabidiol, Pharmaceutically Produced with < 5 ppm THC
Study Phase: Phase 2/Phase 3
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Drug
Study Drug: M5049
Study Phase: Phase 2
View 1 Less Clinical Trial

69 Total Publications

Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial).
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial).
Journal: Phlebology
Published: September 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ramacciotti's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile